N-[(9H-fluoren-9-ylmethoxy)carbonyl]-α-aminoisobutyric acid;
N-FMOC-C-ALPHA-METHYLALANINE;
N-ALPHA-(9-FLUORENYLMETHOXYCARBONYL)-ALPHA-METHYL-L-ALANINE;
N-ALPHA-(9-FLUORENYLMETHOXYCARBONYL)-ALPHA-AMINOISOBUTYRIC ACID;
N-ALPHA-(9-FLUORENYLMETHYLOXYCARBONYL)-AMINOISOBUTYRIC ACID;
N-ALPHA-FMOC-ALPHA-AMINOISOBUTYRIC ACID;
N-ALPHA-FMOC-L-ALPHA-AMINOISOBUTYRIC ACID;
FMoc-2-aMinoisobutyric acid FMoc-α-Methylalanine
They are usually used to pack powder. And they can prevent sunshine and water from getting bad.
The hard carton can protect your products from crashing and getting wet.
Fmoc-2- amino isobutyric acid (FMOC -2- amino-isobutyric acid) is the key intermediate for the preparation of enheterulamine. enzalutamide (1) is chemically known as 4- [3-(4-cyano-3-trifluoromethylphenyl)-5, 5-dimethyl-4-oxo-2-thio-imidazolidan-1-group] -2-fluoro-n-methylbenzenamide. It is a second generation nonsteroidal androgenreceptor (AR) antagonist with a new structure. The preparation technology of Fmoc-2- amino isobutyric acid is described in this paper.
Adding α-amino-isobutyric acid into the round-bottom flask, adding 10% sodium carbonate aqueous solution to stir and dissolve, then add dioxane, slowly drop 10% dioxane solution of 9-fluorene methoxyl carbyl chloride into the reaction solution under the ice bath, react for 2 hours after the drip is completed, and then react for 8 hours at room temperature, add water to dilute. The water layer was extracted with ethyl ether for 4 times, the water layer was placed in an ice bath, the pH value was adjusted with concentrated hydrochloric acid until the Congo red test paper showed blue color, and the white precipitate was extracted with ethyl acetate, washed with water combined with organic liquid, and the organic layer was dried with anhydrous magnesium sulfate, and the product FMOC-2-amino-isobutyric acid was extracted.
Enzalutamide compounds have the chemical formula 4-[3-[4-cyano-3 -(trifluoromethyl) phenyl]-5, 5-dimethyl-4-oxide-2-thioneone - 1-imidazolyl] -2-fluoro-n-methylbenzenamide, the clinical drug, developed by Medivation and Astellas, On August 31, 2012, it was approved by the United States Food and Drug Administration (FDA) to treat advanced male castration-resistant prostate cancer, which has spread or relapsed, named Xtandi [1], The drug is an oral preparation. Enheterulamine (MDV 3100) is an androgen receptor antagonist that blocks androgen binding to androgen receptors and prevents nuclear migration and co-activator recruitment of ligand-receptor complexes. MDV 3100 has also been shown to induce tumor cell apoptosis without agonist activity. MDV 3100 is a candidate for the treatment of castration-resistant prostate cancer.
| Boc-Tyr（But）.Aib | Boc-aib-Ome |
| Aib | Fmoc-Aib-OH |
| 2-Aib-Ome.Hcl | Z-Aib-OH |
| L-Aib-Oet.Hcl | Cbz-Aib-Otbu |
| Boc-Aib-OH | 2-Aib-Ome.Hcl |
1. R&D service available
2. ISO certified manufacturer, quality guarantee
3.A full course of follow-up service during production
4.High cost effective
5.Quality certification documents provided per customer's request
6.Great after-sales service, maintaining close relationship with customer
7.Full resource to help decrease shipping costs
8.Free sample offered to check out quality prior to any payment
9.Payment term negotiated
10.Assit customers deal with affairs in China